- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the publication “Association of the COVID-19 Pandemic With Rates of Prostate Cancer Biopsy and Diagnoses in Black Versus White US Veterans.”. The study used a retrospective analysis of all prostate biopsies performed in the VA system between January 2018 and March 2021, excluding men with a pre-existing diagnosis of prostate cancer. The stu...
|
- Details
- In this UroToday Journal Club, Zach Klaassen discusses part three of the publication "Multiparametric MRI - What Urologists Need to Know" focusing on Targeted Biopsy. Drs. Wallis and Klaassen review the advantages and disadvantages of three different approaches of MRI-targeted biopsy for prostate cancer detection: cognitive fusion, MRI-TRUS fusion, and direct in-bore MRI-guided biopsy. Fusion MR-g...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses “Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer.” This study examines racial disparities in the use of prostate MRI among patients with prostate cancer in the US. The study used a population-based cohort and multiple mediation analysis to identify factors underlining dispa...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the Prostate Cancer and Prostatic Diseases publication entitled, " Association of dynamic change in patient-reported pain with survival in metastatic castrate-sensitive prostate cancer-exploratory analysis of LATITUDE study. " In addition to overall survival, it is important to consider other endpoints. Patient-reported outcomes and quality...
|
- Details
- In this UroToday Journal Club discussion, Zachary Klaassen discusses the publication " The Addition of Docetaxel to Androgen Receptor Axis-Targeted Therapy and ADT in Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis ." There is a clinical conundrum in that while the triplet approaches in both PEACE-1 and ARASENS have proven benefits compared to the ADT-docetaxel-based doublet,...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the European urology publication Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. Darolutamide is one of three agents that's been assessed in this space, and is a structurally d...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the Journal of Clinical Oncology publication Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials led by the MARCAP Consortium. The SANDSTORM meta-analysis evaluated the sequencing of short-term androgen deprivation therapy (AD...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen discusses the Lancet Oncology publication Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. In this publication, the exploratory analysis of pain and health-related quality of life (HRQOL) is presented, looking at sig...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen highlights the PEACE-1 Lancet publication Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. The efficacy and safety of abiraterone plus prednisone, with or without radi...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen highlights the International journal of cancer publication Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial. Abiraterone acetate plus prednisolone previously showed a clear survival advantage in men starting long-term hormone therapy for prostate cancer...
|
